TYK Medicines, Inc (HKG:2410)
Hong Kong · Delayed Price · Currency is HKD 6.67
-0.31 (-4.38%)
Aug 21, 2026, 4:08 PM HKT
TYK Medicines Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| - | - | 0.11 | - | 44.24 | |
Revenue Growth | - | - | - | - | - |
Cost of Revenue | - | - | 0.09 | - | 24.2 |
Gross Profit | - | - | 0.01 | - | 20.04 |
Selling, General & Admin | 102.26 | 78.48 | 108.33 | 59.31 | 33.54 |
Research & Development | 250.25 | 244.06 | 235.45 | 249.25 | 229.81 |
Operating Expenses | 352.51 | 322.54 | 343.78 | 308.56 | 263.35 |
Operating Income | -352.51 | -322.54 | -343.76 | -308.56 | -243.31 |
Interest Expense | -15.39 | -14.92 | -12.57 | -8.73 | -3.26 |
Interest & Investment Income | 2.74 | 2.74 | 3.28 | 3.73 | 7.37 |
Currency Exchange Gain (Loss) | -5.12 | -5.12 | 0.29 | 0.1 | - |
Other Non Operating Income (Expenses) | 147.69 | 26.23 | -35.17 | -68.98 | -72.87 |
EBT Excluding Unusual Items | -226.42 | -313.61 | -387.93 | -382.44 | -312.06 |
Gain (Loss) on Sale of Investments | - | - | - | -0.73 | 0.34 |
Gain (Loss) on Sale of Assets | 4.92 | 4.92 | - | -0.01 | -0.04 |
Other Unusual Items | 2.71 | 2.71 | 0 | 0.01 | -0.05 |
Pretax Income | -218.79 | -305.97 | -387.93 | -383.17 | -311.8 |
Earnings From Continuing Operations | -218.79 | -305.97 | -387.93 | -383.17 | -311.8 |
Minority Interest in Earnings | 6.3 | 6.2 | 0.97 | 0.74 | 0.81 |
Net Income | -212.49 | -299.77 | -386.96 | -382.43 | -310.99 |
Net Income to Common | -212.49 | -299.77 | -386.96 | -382.43 | -310.99 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 365 | 375 | 338 | 289 | 278 |
Shares Outstanding (Diluted) | 365 | 375 | 338 | 289 | 278 |
Shares Change | 0.70% | 10.94% | 16.91% | 3.94% | - |
EPS (Basic) | -0.58 | -0.80 | -1.15 | -1.32 | -1.12 |
EPS (Diluted) | -0.58 | -0.80 | -1.15 | -1.32 | -1.12 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Free Cash Flow | - | -255.18 | -381.87 | -277.32 | -279.02 |
Free Cash Flow Per Share | - | -0.68 | -1.13 | -0.96 | -1.00 |
Gross Margin | - | - | 13.08% | - | 45.30% |
Operating Margin | - | - | -321274.77% | - | -549.94% |
Profit Margin | - | - | -361640.19% | - | -702.94% |
Free Cash Flow Margin | - | - | -356891.59% | - | -630.67% |
EBITDA | -340.33 | -310.26 | -328.83 | -295.1 | -232.31 |
D&A For EBITDA | 12.18 | 12.28 | 14.93 | 13.46 | 11 |
EBIT | -352.51 | -322.54 | -343.76 | -308.56 | -243.31 |